Edwards Lifesciences Corp (EW) stock
Close on Nov 11, 2026Market cap $60.99BP/E 59.8Yield –
Edwards Lifesciences Corp grew revenue 13.4% to $6.67B over the twelve months to Sep 30, 2026. Operating income rose 1.1% to $1.44B, moving the operating margin from 24.2% to 21.6%. Free cash flow was $1.42B, up 77.1% from a year earlier. At the latest close the market valued the company at $60.99B, 59.8 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $60.99B
- P/E ratio
- 59.8
- Price to sales
- 9.14
- Price to book
- 5.62
- Dividend yield
- –
- Free cash flow yield
- 2.34%
Fundamentals
- Revenue
- $6.67B
- Net income
- $1.02B
- EPS, diluted
- $1.77
- Free cash flow
- $1.42B
- Book value per share
- $18.80
- Diluted shares
- 578M
Trading
- Next earnings
- Feb 9, 2027 (estimated, after the close)
- Previous close
- $104.01
- Open
- $103.76
- Day's range
- $102.73 – $106.05
- Volume
- 4,252,321
- Average volume (20 days)
- 4,858,983
- Index membership
- S&P 500, Russell 1000, Russell 3000
- Beta (5 years)
- 0.97
- 52-week range
- $74.66 – $106.05
- RSI (14 days)
- 78.9
- Volatility (1 year)
- 25.6%
- Relative volume
- 1.04×
- WACC
- 9.7%
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | EW | S&P 500 | Difference | EW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +24.2% | -2.4% | +26.6 pts | ||
| 3 months | +13.0% | -1.2% | +14.1 pts | ||
| Year to date | +24.1% | +12.3% | +11.8 pts | ||
| 1 year | +24.2% | +12.4% | +11.8 pts | ||
| 3 years | +64.8% | +78.8% | −14.0 pts | +18.1% | +21.4% |
| 5 years | -7.4% | +75.2% | −82.6 pts | -1.5% | +11.9% |
| 10 years | +248.8% | +311.1% | −62.3 pts | +13.3% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Edwards Lifesciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Update
About Edwards Lifesciences
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Edwards Lifesciences Corporation develops and manufactures medical devices focused on structural heart disease. The company's business encompasses surgical and catheter-based therapies across three core product groups: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, and Surgical Structural Heart. Its portfolio features artificial tissue replacement valves, repair platforms, and annuloplasty rings designed to address valvular conditions affecting the aortic, mitral, tricuspid, and pulmonary heart valves. Edwards Lifesciences provides these technologies to healthcare providers, serving physicians, cardiac surgeons, interventional cardiologists, nurses, hospital systems, and procurement organizations.
Company profile, executives and historyEdwards Lifesciences stock: common questions
What is Edwards Lifesciences's stock price?
EW closed at $105.81 on Nov 11, 2026, up 1.73% on the day. Over the past 52 weeks it traded between $74.66 and $106.05.
What is Edwards Lifesciences's market cap?
Edwards Lifesciences was worth $60.99B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is EW's P/E ratio?
EW trades at 59.8 times earnings, based on diluted earnings per share of $1.77 over the twelve months to Sep 30, 2026.
How much revenue does Edwards Lifesciences make?
Edwards Lifesciences reported revenue of $6.67B for the twelve months to Sep 30, 2026, up 13.4% from a year earlier.
Does Edwards Lifesciences pay a dividend?
No. Edwards Lifesciences has not paid a cash dividend over the last twelve months.
When does Edwards Lifesciences report earnings next?
Edwards Lifesciences is expected to report Q4 FY2026 results on Feb 9, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has EW stock performed over the past year?
Including dividends, EW returned +24.2% over the past year, against +12.4% for the S&P 500.
How many EW shares are sold short?
9M shares were sold short at the latest FINRA report, 1.63% of the float, or 2.8 days of average trading volume.
Who are Edwards Lifesciences's competitors?
Companies most similar to Edwards Lifesciences by business, industry and size include ISRG, STE, SNN, ENOV, BAX.
See a number that looks wrong?